Cutaneous follicle center lymphoma, intrapelvic lymph nodes
ICD-10 C82.66 is a billable code used to indicate a diagnosis of cutaneous follicle center lymphoma, intrapelvic lymph nodes.
Cutaneous follicle center lymphoma (CFCL) is a subtype of non-Hodgkin lymphoma that primarily affects the skin and is characterized by the proliferation of follicle center (germinal center) B-cells. When CFCL involves the intrapelvic lymph nodes, it indicates a more advanced stage of the disease, often associated with systemic symptoms. Patients may present with localized skin lesions, which can be mistaken for other dermatological conditions. The disease can manifest with B-symptoms such as fever, night sweats, and weight loss, which are indicative of systemic involvement. Diagnosis typically involves a combination of clinical examination, imaging studies, and biopsy of affected lymph nodes or skin lesions. Treatment protocols may include localized therapies such as radiation, systemic therapies like chemotherapy, or targeted therapies depending on the stage and severity of the disease. The prognosis varies based on the extent of lymph node involvement and the presence of B-symptoms, necessitating careful staging and monitoring.
Detailed clinical notes on patient history, physical examination findings, and treatment plans.
Patients presenting with skin lesions and systemic symptoms, requiring biopsy and staging.
Ensure accurate staging and documentation of B-symptoms for treatment planning.
Comprehensive skin examination notes, including lesion descriptions and biopsy results.
Patients with cutaneous lesions that may be misdiagnosed as benign skin conditions.
Collaboration with oncology for accurate diagnosis and treatment planning.
Used when a biopsy is performed to confirm the diagnosis of CFCL.
Pathology report must be included in the patient's medical record.
Ensure that the pathology report clearly indicates the diagnosis and any relevant findings.
Common symptoms include skin lesions, fever, night sweats, and unexplained weight loss, which may indicate systemic involvement.
